Ketamine has been used as a surgical anesthesia around the world for more than 50 years. About 20 years ago, ketamine’s ability to relieve depression, anxiety, and some pain disorders in less than 24 hours after administration was stumbled upon by researchers. Follow up studies replicating the rapid results have changed researchers’ understanding of depression, revitalizing an area of medical research that had been stagnant for almost three decades. Esketamine, or Spravato®, is derived from ketamine and makes its powerful antidepressant relief available in the form of a intra-nasal spray, similar to a common nasal decongestant. Psychiatric Solutions offers esketamine therapy in our Spokane office, and this novel therapy for treatment-resistant depression can be combined with other treatments, such as antidepressants, Transcranial Magnetic Stimulation (TMS), or other therapies.
Esketamine, or Spravato®, is the first nasal spray medication that is a treatment for depression. Combined with an antidepressant, Spravato® is FDA-approved to treat treatment-resistant depression and has been clinically shown to improve symptoms of depression in just 4 weeks.
During or shortly after treatment, esketamine therapy patients generally report some sedation and disassociation effects. Other side effects may include nausea, dizziness, vertigo, or headache.